Literature DB >> 12744577

A controlled trial of modified electroconvulsive therapy in schizophrenia in a Nigerian teaching hospital.

D I Ukpong1, R O A Makanjuola, O Morakinyo.   

Abstract

The efficacy of ECT in the treatment of Schizophrenia was investigated in a double blind controlled trial. The ICD-10 criteria for Schizophrenia were fulfilled by the 20 patients who entered the trial. Consecutive individuals who satisfied the inclusion criteria were randomly allocated to a course of (bilateral) six real or simulated ECTs each as applicable. Sixteen patients completed the ECT treatment and 20 weeks follow up period. Analysis of measures of clinical change (BPRS and SANS Scores) showed that both groups of patients improved, but the improvement of patients receiving ECT was not significantly greater than that of the control group.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12744577     DOI: 10.4314/wajm.v21i3.28039

Source DB:  PubMed          Journal:  West Afr J Med        ISSN: 0189-160X


  4 in total

Review 1.  Electroconvulsive Therapy and Schizophrenia: A Systematic Review.

Authors:  Sana A Ali; Nandita Mathur; Anil K Malhotra; Raphael J Braga
Journal:  Mol Neuropsychiatry       Date:  2019-04-02

2.  Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?

Authors:  Marianna Purgato; Clive Adams; Corrado Barbui
Journal:  Int J Ment Health Syst       Date:  2012-07-06

3.  Electroconvulsive therapy for treatment-resistant schizophrenia.

Authors:  Diarmid Jm Sinclair; Sai Zhao; Fang Qi; Kazare Nyakyoma; Joey Sw Kwong; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2019-03-19

4.  Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis.

Authors:  Saeed Ahmed; Ali Mahmood Khan; Hema Madhuri Mekala; Hema Venigalla; Rizwan Ahmed; Amira Etman; Michael Esang; Mustafa Qureshi
Journal:  Heliyon       Date:  2017-11-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.